Evidence map›Paper›PMID 41591483›Full record

ArticleCancer immunology, immunotherapy : CII2026

Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.

Kenta Takahashi, Daiki Ikarashi, Shigehisa Kitano, Daichi Tamura, Masakazu Abe, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenta Takahashi *Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Daiki Ikarashi *Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Shigehisa Kitano *Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp.ORCID http://orcid.org/0000-0002-4041-8298
Daichi TamuraDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Masakazu AbeDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Ayato ItoDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Ei ShiomiDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Shigekatsu MaekawaDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Renpei KatoDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Mitsugu KanehiraDepartment of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Naoki YanagawaDepartment of Pathology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Wataru Obara *Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association between the tumor immune microenvironment (TiME) in upper tract urothelial carcinoma (UTUC) and its prognosis remains unclear. We investigated the relationship between TiME and UTUC recurrence patterns.

methodsWe evaluated 90 patients who underwent nephroureterectomy for UTUC and divided them into nonrecurrence, distant metastasis, and intravesical recurrence-only groups. We assessed the association of the TiME with clinicopathological factors using surgical tissues and the prognosis of the three groups via multiplex fluorescence immunohistochemistry.

resultsThe median age was 71 years (44-89), and 58 (64%) were male. Intratumoral CD4

conclusionsOur study demonstrated that CD4

Indexed as

Carcinoma, Transitional CellNeoplasm Recurrence, LocalTumor MicroenvironmentUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisT-Lymphocytes, RegulatoryDistant metastasisNephroureterectomyRegulatory T cellTumor immune microenvironmentUpper tract urothelial carcinoma

Identifiers

PMID41591483
PMCPMC12847598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.